白塞补泻颗粒治疗白塞病20例临床评价  

Clinical Evaluation of Baisai Buxie Granule for Treating Behcet's Disease in 20 Cases

作　　者：石海军[1] 尹国富[1] 刘福华[1] 岳敏[1] 

机构地区：[1]山东省潍坊市中医院,山东潍坊261021

出　　处：《中国药业》2017年第16期38-40,共3页China Pharmaceuticals

基　　金：山东省潍坊市中医药科研计划项目[2013-020]

摘　　要：目的探讨白塞补泻颗粒治疗白塞病(BD)的临床疗效。方法选取医院收治的白塞病患者40例,将其随机分为试验组和对照组,各20例。对照组患者给予常规西药(沙利度胺)治疗,试验组患者给予白塞补泻颗粒。结果试验组总有效率为90.00%,明显高于对照组的75.00%(P<0.05);治疗后,试验组口苦、眼部病变、乏力、口腔溃疡评分明显低于对照组,C反应蛋白(CRP)及红细胞沉降率(ESR)水平明显低于对照组(P<0.05);试验组不良反应发生率为15.00%,与对照组的10.00%比较,差异无显著性(P>0.05);试验组复发率为15.00%,明显低于对照组的45.00%(P<0.05)。结论白塞补泻颗粒治疗白塞病,有利于促进临床症状改善,减轻炎性反应,降低血沉,值得临床推广。Objective To investigate the clinical effect of Baisai Buxie Granule in treating Behcet ＇ s disease（ BD）. Methods Totally 40 patients with BD in our hospital were selected and randomly divided into the experimental group and the control group,20 cases in each group. The control group was treated with conventional western medicine（ thalidomide） and the experimental group was treated with Baisai Buxie Granule. Results The total effective rate of the experimental group was 90. 00%,which was significantly higher than 75. 00% of the control group（ P 0. 05）. After treatment,the scores of bitter taste,eye diseases,fatigue and oral ulcer,the levels of CRP and ESR in the experimental group were significantly lower than those in the control group（ P 0. 05）. The incidence rates of adverse reactions in the experimental group and the control group were 15. 00% and 10. 00% without significant difference（ P〈0. 05）. The recurrence rate of the experimental group was 15. 00%,which was significantly lower than 45. 00% of the control group（ P〈0. 05）.Conclusion Baisai Buxie Granule in treating BD is beneficial to promote the improvement of clinical symptoms,reduce the inflammatory reaction and the ESR. It is worthy of clinical promotion.

关 键 词：白塞病 白塞补泻颗粒 C反应蛋白 临床疗效 

分 类 号：R285.6[医药卫生—中药学] R593[医药卫生—中医学]